Global Cancer Gene Therapy Market Overview:
Global Cancer Gene Therapy Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Cancer Gene Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Cancer Gene Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Cancer Gene Therapy Market:
The Cancer Gene Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Cancer Gene Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Cancer Gene Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Cancer Gene Therapy market has been segmented into:
Oncolytic Virotherapy
Gene Transfer Therapy
Gene-Induced Immunotherapy).
By Application, Cancer Gene Therapy market has been segmented into:
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer Gene Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Cancer Gene Therapy market.
Top Key Players Covered in Cancer Gene Therapy market are:
Adaptimmune Therapeutics plc
Advantagene Inc.
Altor Bioscience (a NANT Company)
Anchiano Therapeutics Inc.
bluebird bio Inc.
Genelux Corporation
GlaxoSmithKline PLC
Merck & Co. Inc.
OncoGenex Pharmaceuticals Inc.
Shanghai Sunway Biotech Co. Ltd.
Shenzhen SiBiono GeneTech Co. Ltd.
ZIOPHARM Oncology Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Cancer Gene Therapy Market Type
4.1 Cancer Gene Therapy Market Snapshot and Growth Engine
4.2 Cancer Gene Therapy Market Overview
4.3 Oncolytic Virotherapy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Oncolytic Virotherapy: Geographic Segmentation Analysis
4.4 Gene Transfer Therapy
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Gene Transfer Therapy: Geographic Segmentation Analysis
4.5 Gene-Induced Immunotherapy).
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Gene-Induced Immunotherapy).: Geographic Segmentation Analysis
Chapter 5: Cancer Gene Therapy Market Application
5.1 Cancer Gene Therapy Market Snapshot and Growth Engine
5.2 Cancer Gene Therapy Market Overview
5.3
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 : Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Cancer Gene Therapy Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ADAPTIMMUNE THERAPEUTICS PLC; ADVANTAGENE
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; ALTOR BIOSCIENCE (A NANT COMPANY); ANCHIANO THERAPEUTICS
6.4 INC.; BLUEBIRD BIO
6.5 INC.; GENELUX CORPORATION; GLAXOSMITHKLINE PLC; MERCK & CO.
6.6 INC.; ONCOGENEX PHARMACEUTICALS
6.7 INC.; SHANGHAI SUNWAY BIOTECH CO.
6.8 LTD.; SHENZHEN SIBIONO GENETECH CO.
6.9 LTD.; ZIOPHARM ONCOLOGY
6.10 INC.
Chapter 7: Global Cancer Gene Therapy Market By Region
7.1 Overview
7.2. North America Cancer Gene Therapy Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Oncolytic Virotherapy
7.2.2.2 Gene Transfer Therapy
7.2.2.3 Gene-Induced Immunotherapy).
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Cancer Gene Therapy Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Oncolytic Virotherapy
7.3.2.2 Gene Transfer Therapy
7.3.2.3 Gene-Induced Immunotherapy).
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Cancer Gene Therapy Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Oncolytic Virotherapy
7.4.2.2 Gene Transfer Therapy
7.4.2.3 Gene-Induced Immunotherapy).
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Cancer Gene Therapy Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Oncolytic Virotherapy
7.5.2.2 Gene Transfer Therapy
7.5.2.3 Gene-Induced Immunotherapy).
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Cancer Gene Therapy Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Oncolytic Virotherapy
7.6.2.2 Gene Transfer Therapy
7.6.2.3 Gene-Induced Immunotherapy).
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Cancer Gene Therapy Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Oncolytic Virotherapy
7.7.2.2 Gene Transfer Therapy
7.7.2.3 Gene-Induced Immunotherapy).
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Cancer Gene Therapy Scope:
|
Report Data
|
Cancer Gene Therapy Market
|
|
Cancer Gene Therapy Market Size in 2025
|
USD XX million
|
|
Cancer Gene Therapy CAGR 2025 - 2032
|
XX%
|
|
Cancer Gene Therapy Base Year
|
2024
|
|
Cancer Gene Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Adaptimmune Therapeutics plc, Advantagene Inc., Altor Bioscience (a NANT Company), Anchiano Therapeutics Inc., bluebird bio Inc., Genelux Corporation, GlaxoSmithKline PLC, Merck & Co. Inc., OncoGenex Pharmaceuticals Inc., Shanghai Sunway Biotech Co. Ltd., Shenzhen SiBiono GeneTech Co. Ltd., ZIOPHARM Oncology Inc..
|
|
Key Segments
|
By Type
Oncolytic Virotherapy
Gene Transfer Therapy
Gene-Induced Immunotherapy).
By Applications
|
